Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Radical -xh acid – or anhydride – acid halide or salt thereof...
Patent
1998-02-09
2000-07-04
Travers, Russell
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Radical -xh acid, or anhydride, acid halide or salt thereof...
514569, 514379, A61K 3142, A61K 3119
Patent
active
060839856
DESCRIPTION:
BRIEF SUMMARY
TECHNICAL FIELD
The present invention is useful in the medicinal field. In particular, the present invention relates to an antitumor or anti-AIDS composition containing a protein-farnesyltransferase (PFT) inhibitor and an agent which decreases farnesyl pyrophosphate in vivo as active ingredients.
BACKGROUND ART
The ras oncogenes are activated through mutation and their translation products, the Ras proteins, play an important role in transformation of normal cells to cancer cells. Active ras oncogenes are observed in many types of cancer such as colorectal cancer and pancreatic cancer, reportedly in about 25% of human cancers. Accordingly, suppression of activation of the ras oncogenes or inhibition of the function of their products, the Ras protein, leads to prevention of carcinogenesis and is expected to produce an antitumor effect.
On the other hand, it has been revealed recently that the Ras proteins require their farnesylation in order to function and that inhibition of farnesylation prevents the Ras proteins from localizing on cell membranes and thus blocks carcinogenic transformation of cells. The activation of the Ras oncoproteins can be depressed by inhibiting protein-farnesyltransferase (PFT), the enzyme which catalyses farnesylation of the Ras proteins. Since the enzyme is involved in farnesylation of a limited number of proteins in the body, PFT inhibitors are promising as safe and selective antitumor agents. From this standpoint, a number of PFT inhibitors have been developed recently [Cell, vol. 57, 1167-1177 (1989); Proc. Natl. Acad. Sci, vol. 86, 8323-8327 (1989); Proc. Natl. Acad, Sci, vol. 90, 2281-2285 (1993); Science, vol. 245, 379-385 (1989); Science, vol. 260, 1934-1937 (1993); Science, vol. 260, 1937-1942 (1993); J. Biol. Chem., vol. 266, 15575-15578 (1991); J. Antibiotics, vol. 46, 222-227 (1993); Japanese Unexamined Patent Publication JP-A-5-201869; Japanese Unexamined Patent Publication JP-A-5-213992].
Recent study by the present inventors demonstrated that these PFT inhibitors can block the reactivation of static viruses by suppressing development of matured Ras proteins and are useful as anti-AIDS (HIV) agents (Japanese Patent Application JP6-331691).
However, in order to development them as drugs, there still remain problems that most of these PFT inhibitors have low activities in cells and do not have sufficient effect in vivo.
It is reported that agents which decrease farnesyl pyrophosphate in vivo, especially those which inhibit biosynthesis of farnesyl pyrophosphate such as hydroxymethylglutaryl CoA reductase (HMG CoA reductase) inhibitors are expected to exert antitumor effect by suppressing the functioning of the Ras oncoproteins [J. Biol Chem., vol. 265, 19937-19941 (1990)]. However, these agents exhibit quite insufficient antitumor activities when they are used alone.
DISCLOSURE OF INVENTION
The object of the present invention is to provide a novel antitumor or anti-AIDS agent which suppresses the function of, the Ras oncoprotein and thereby exerts antitumor or anti-AIDS effect.
The present inventors have found that compositions containing a protein-farnesyltransferase inhibitor in combination with an agent which decreases farnesyl pyrophosphate in vivo suppresses the function of the Ras oncoproteins remarkably and are useful as antitumor or anti-AIDS agents, and have accomplished the present invention.
The present invention provides an antitumor or anti-AIDS composition containing a protein-farnesyltransferase inhibitor and an agent which decreases farnesyl pyrophosphate in vivo as active ingredients.
The symbols and terms used herein will be explained.
There is no restriction on the agent which decreases farnesyl pyrophosphate in vivo, as long as it is a pharmaceutically acceptable agent having such an action. For example, inhibitors of biosynthesis of farnesyl pyrophosphate are preferred. In particular, agents which inhibit biosynthesis of farnesyl pyrophosphate such as hydroxymethylglutaryl CoA reductase inhibitors like lovastatin, simvastatin, pravastatin an
REFERENCES:
patent: 5643958 (1997-07-01), Iwasawa et al.
117CA163498s Sumi et al, 1992.
Iwasawa Yoshikazu
Tanaka Kenji
Yonemoto Mari
Banyu Pharmaceutical Co. Ltd.
Travers Russell
LandOfFree
Medicinal composition does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Medicinal composition, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Medicinal composition will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1486999